NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,448.47 -129.83 (-0.70%) CRUDE OIL
78.56 +0.08 (+0.10%) GOLD FUTURES
2,329.10 -2.10 (-0.09%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,727.67 -482.81 (-0.94%)
Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous close | 1.1400 |
| Open | 1.1300 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1200 |
| Day's range | 1.0700 - 1.1600 |
| 52-week range | 1.0700 - 3.1300 |
| Volume | |
| Avg. volume | 377,713 |
| Market cap | 81.381M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 12.33 |
| EPS (TTM) | 0.0900 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
PR NewswireProtalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
Insider MonkeyProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
- GuruFocus.com
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth
